Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) to Post Q2 2022 Earnings of ($0.36) Per Share, Jefferies Financial Group Forecasts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Rating) – Jefferies Financial Group issued their Q2 2022 earnings per share estimates for Verrica Pharmaceuticals in a report released on Monday, May 9th. Jefferies Financial Group analyst C. Ezell expects that the company will post earnings of ($0.36) per share for the quarter. Jefferies Financial Group also issued estimates for Verrica Pharmaceuticals’ Q3 2022 earnings at ($0.46) EPS, Q4 2022 earnings at ($0.61) EPS, FY2022 earnings at ($1.79) EPS, FY2023 earnings at ($1.05) EPS, FY2024 earnings at $0.14 EPS, FY2025 earnings at $0.97 EPS and FY2026 earnings at $2.43 EPS.

VRCA has been the subject of several other reports. Brookline Capital Acquisition initiated coverage on shares of Verrica Pharmaceuticals in a report on Thursday, March 10th. They set a “buy” rating and a $20.00 price target for the company. HC Wainwright restated a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Monday, March 7th. Zacks Investment Research upgraded shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price objective for the company in a research report on Friday. Brookline Capital Management reiterated a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Thursday, March 10th. Finally, Needham & Company LLC decreased their price objective on shares of Verrica Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, March 3rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verrica Pharmaceuticals currently has an average rating of “Buy” and an average price target of $16.89.

Shares of VRCA stock opened at $5.66 on Thursday. Verrica Pharmaceuticals has a 12-month low of $5.20 and a 12-month high of $14.79. The company has a market capitalization of $155.76 million, a P/E ratio of -3.63 and a beta of 1.96. The firm has a 50-day moving average price of $7.60 and a 200 day moving average price of $8.83.

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) last released its quarterly earnings data on Wednesday, March 2nd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.13.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its position in shares of Verrica Pharmaceuticals by 23.1% in the fourth quarter. BlackRock Inc. now owns 794,466 shares of the company’s stock worth $7,278,000 after purchasing an additional 149,248 shares in the last quarter. Geode Capital Management LLC increased its holdings in Verrica Pharmaceuticals by 11.8% during the third quarter. Geode Capital Management LLC now owns 238,069 shares of the company’s stock worth $2,975,000 after buying an additional 25,089 shares during the last quarter. Morgan Stanley increased its holdings in Verrica Pharmaceuticals by 2,540.4% during the second quarter. Morgan Stanley now owns 122,065 shares of the company’s stock worth $1,380,000 after buying an additional 117,442 shares during the last quarter. Millennium Management LLC increased its holdings in Verrica Pharmaceuticals by 466.6% during the fourth quarter. Millennium Management LLC now owns 94,220 shares of the company’s stock worth $863,000 after buying an additional 77,590 shares during the last quarter. Finally, MML Investors Services LLC increased its holdings in Verrica Pharmaceuticals by 13.4% during the fourth quarter. MML Investors Services LLC now owns 50,875 shares of the company’s stock worth $466,000 after buying an additional 6,000 shares during the last quarter. 34.58% of the stock is currently owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals (Get Rating)

Verrica Pharmaceuticals Inc, a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

Recommended Stories